- SR-9011
-
- $0.00 / 1kg
-
2026-02-02
- CAS:1379686-29-9
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 1000kg
- SR9011
-
- $0.00 / 1kg
-
2026-01-19
- CAS:1379686-29-9
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 10T
- SR9011
-
- $5.00 / 1Box
-
2026-01-19
- CAS:1379686-29-9
- Min. Order: 1Box
- Purity: 99.99%
- Supply Ability: 20000 boxes
|
| Product Name: | SR9011 | | Synonyms: | SR-9011;SR 9011;SR9011;CS-2028;SR9011;SR9001;3-[[[(4-Chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-N-pentyl-1-pyrrolidinecarboxamide;Stenabolic Sr9011;White Powder SR9011Cas# 1379686-29-9 Raw Chemical Material;SR-9011;SR 9011 | | CAS: | 1379686-29-9 | | MF: | C23H31ClN4O3S | | MW: | 479.04 | | EINECS: | 1379686-290-9 | | Product Categories: | 1379686-29-9;SARMS | | Mol File: | 1379686-29-9.mol |  |
| | SR9011 Chemical Properties |
| Boiling point | 642.8±50.0 °C(Predicted) | | density | 1.254±0.06 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,Store in freezer, under -20°C | | solubility | Chloroform (Slightly), Methanol (Slightly) | | form | Solid | | pka | 14.71±0.40(Predicted) | | color | Dark Yellow to Very Dark Brown | | InChI | InChI=1S/C23H31ClN4O3S/c1-2-3-4-12-25-23(29)27-13-11-19(16-27)15-26(14-18-5-7-20(24)8-6-18)17-21-9-10-22(32-21)28(30)31/h5-10,19H,2-4,11-17H2,1H3,(H,25,29) | | InChIKey | PPUYOYQTTWJTIU-UHFFFAOYSA-N | | SMILES | N1(C(NCCCCC)=O)CCC(CN(CC2=CC=C(Cl)C=C2)CC2SC([N+]([O-])=O)=CC=2)C1 |
| | SR9011 Usage And Synthesis |
| Biochem/physiol Actions | SR9011 is a potent nuclear receptor REV-ERB agonist (EC50 of REV-ERBα- and REV-ERBβ-dependent repressor activity = 790 and 560 nM, respectively, by cell-based reporter assay) that stimulates REV-ERB-dependent target genes suppression both in cultures in vitro and in mice in vivo (100 mg/kg i.p., b.i.d.) without activity toward a panel of 46 other nuclear receptors. SR9011 is shown to modulate circadian behavior by suppressing the transcription factors BMAL1 (brain and muscle ARNT-like protein 1) and CLOCK (circadian locomotor output cycles kaput) as well as induce energy expenditure and weight loss by regulating genes involved in lipid and glucose metabolism in mice in vivo with good bioavailabiilty (plasma conc. = 0.53 and 15.3 μM 2 hr post 10 or 100 mg/kg i.p. dosage; brain conc. = 0.24 μM 2 hr post 10 mg/kg i.p.), while its structure analog GSK4112 shows no plasma exposure. | | Uses | SR 9011 is a synthetic REV-ERBα/β agonist with activity in vivo. It is a lead compound for a new class of cancer drugs associated with the body’s circadian clock. | | Application | SR9011 has been used as a nuclear receptor subfamily 1 group D member 1 (NR1D1) receptor agonist:
to study its effects on microglial immune-metabolism
to study its effects on insulin secretion from human type 2 diabetes islet cells
to study its effects on thyroid-stimulating hormone β (TSHβ) gene expression | | Side effects | After a close investigation of the effects of SR9011 on humans, it is deduced that the drug is well tolerated without any significant side effects. However, minor effects on sleep, such as transient insomnia, were reported by some users. Nevertheless, it is always best to stick to the given drug dose if you don’t want to experience any harm.
| | in vivo | SR9011 displays reasonable plasma exposure, thus, the expression of REV-ERB responsive genes is examined in the liver of mice treated with various doses of SR9011 for 6-days. The plasminogen activator inhibitor type 1 gene (Serpine1) is a REV-ERB target gene and displays dose-dependent suppression of expression in response to SR9011. The cholesterol 7α-hydroxylase (Cyp7a1) and sterol response element binding protein (Srepf1) genes have also been shown to be responsive to REV-ERB and are dose-dependently suppressed with increasing amounts of SR9011. After 12 days in D:D conditions mice are injected with a single dose of SR9011 or vehicle at CT6 (peak expression of Rev-erbα). Vehicle injection causes no disruption in circadian locomotor activity. However, administration of a single dose of SR9011 results in loss of locomotor activity during the subject dark phase. Normal activity returns the next circadian cycle, consistent with clearance of the drugs in less than 24h. The SR9011-dependent decrease in wheel running behavior in the mice under constant darkness conditions is dose-dependent and that the potency (ED50=56 mg/kg) is similar to the potency of SR9011-mediated suppression of a REV-ERB responsive gene, Srebf1 , in vivo (ED50=67mg/kg)[1]. |
| | SR9011 Preparation Products And Raw materials |
|